Tenax Therapeutics Inc. (TENX)
NASDAQ: TENXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TENX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $56.92M
- EPS (TTM)
- -$1.39
- Dividend yield
- None
- 52-week range
- 1.24 – 19.40
- Day range
- 1.24 – 1.35
- Volume / Avg
- 2.28M / 3.15M
- Beta
- —
- Shares outstanding
- 45.54M
52-week range
TENX stock today
Tenax Therapeutics (TENX) closed at $1.25 on Nov 20, down 10.07% (-$0.14), versus the S&P 500's 3.70% decline. Shares are 93.6% below their 52-week high of $19.40, set on Jul 9, 2026 and 0.8% above the 52-week low of $1.24, near the bottom of the past year's range. TENX is down 89.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 84.7%.
Tenax Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tenax Therapeutics
Company profileTenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Christopher T. Giordano
- Headquarters
- Chapel Hill, NC
- Employees
- 14
- Website
- tenaxthera.com
Financial highlights
Full financialsIn fiscal 2025, Tenax Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Tenax Therapeutics reported a net loss of $52.6 million, compared with a loss of $17.6 million a year earlier. Diluted earnings per share came in at -$1.34.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-52.60M | $-17.60M | $-7.71M | $11.05M | $-32.47M |
| EPS (diluted) | $-1.34 | $-1.15 | $-31.04 | — | $-1.58 |
Analyst forecast
ForecastConsensus (10 analysts)
none
Avg. price target
$12.56+904.80%
- Strong buy 1
- Buy 5
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.31 vs $-0.35
- Surprise
- +11.43%
TENX news
All TENX news- TENX Investors Have Rights - If You Lost Money Investing in Tenax Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your LossesPR Newswire
- INVESTOR REMINDER: Berger Montague Notifies Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors of a Class Action Lawsuit and DeadlinePR Newswire
- Pomerantz Law Firm Announces the Filing of a Class Action Against Tenax Therapeutics, Inc. and Certain Officers - TENXPR Newswire
- Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TENXPR Newswire
- INVESTOR DEADLINE: Tenax Therapeutics, Inc. (TENX) Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 DeadlinePR Newswire
- TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS LawPR Newswire
- TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud LawsuitPR Newswire
- Tenax Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TENXPR Newswire
Tenax Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IBIOiBio Inc. | 0.8001 | -0.11% | $56.37M | vs TENX |
| KZIAKazia Therapeutics Limited ADR | 4.92 | -8.38% | $56.22M | vs TENX |
| AZRAzora Therapeutics Inc. | 3.85 | -0.52% | $55.00M | vs TENX |
| RANIRani Therapeutics Holdings Inc. Class A | 0.5111 | -11.97% | $59.03M | vs TENX |
| BOLDBoundless Bio Inc. | 2.32 | -2.52% | $54.78M | vs TENX |
| XLOXilio Therapeutics Inc. | 7.56 | -1.11% | $53.40M | vs TENX |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs TENX |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs TENX |
Indexes, lists and sector
Tenax Therapeutics stock FAQ
What is Tenax Therapeutics's stock price today?
TENX last traded at $1.25 as of Nov 20, 4:00 PM EST, down 10.07% on the day. Prices are delayed at least 15 minutes.
Does Tenax Therapeutics pay a dividend?
No. Tenax Therapeutics does not currently pay a regular cash dividend.
Who is Tenax Therapeutics's CEO?
Mr. Christopher T. Giordano is the chief executive officer of Tenax Therapeutics Inc., which has about 14 employees.
Has TENX ever split its stock?
Yes. The most recent TENX stock split was a 1-for-80 split on Jan 3, 2024, one of 5 splits on record.
What is the TENX 52-week high?
The 52-week high for TENX is $19.40 and the 52-week low is $1.24. The stock is currently 93.6% below its high.